公开(公告)号：AU2007338754A1

公开(公告)日：2008-07-03

申请号：AU2007338754

申请日：2007-12-21

Applicant: VERTEX PHARMA

Inventor： YOUNG STEPHEN CLINTON ,  KNEGTEL RONALD ,  CHARRIER JEAN DAMIEN ,  BRENCHLEY GUY ,  DURRANT STEVEN ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  PINDER JOANNE LOUISE ,  RUTHERFORD ALISTAIR PETER ,  EVERITT SIMON ROBERT LORRIE

IPC: A61K31/506 ,  A61K31/551 ,  A61P3/00 ,  A61P5/00 ,  A61P9/00 ,  A61P11/06 ,  A61P19/00 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/08 ,  A61P43/00

Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention also provides processes for preparing the compounds of the invention.

公开(公告)号：BRPI0508102A

公开(公告)日：2007-07-17

申请号：BRPI0508102

申请日：2005-02-28

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  DURRANT STEVEN ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  RUTHERFORD ALISTAIR ,  RAMAYA SHARN ,  STUDLEY JOHN R ,  TRUDEAU MARTIN ,  LOOKER ADAM

IPC: C07D405/12 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/443 ,  A61K38/04 ,  A61K38/06 ,  C07D207/16 ,  C07D209/52 ,  C07D401/12 ,  C07D401/14 ,  C07D417/06 ,  C07D417/12 ,  C07K5/02 ,  C07K5/04

Abstract: The present invention provides a compound of formula (I): wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.

公开(公告)号：NO20064344L

公开(公告)日：2006-10-19

申请号：NO20064344

申请日：2006-09-26

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  MORTIMORE MICHAEL ,  DURRANT STEVEN ,  STUDLEY JOHN R ,  O'DONNELL MICHAEL ,  RUTHERFORD ALISTAIR ,  RAMAYA SHARN ,  TRUDEAU MARTIN ,  LOOKER ADAM

IPC: C07D207/16 ,  A61K38/04 ,  A61K38/06 ,  C07D209/52 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D417/06 ,  C07D417/12 ,  C07K5/02 ,  C07K5/04

Abstract: The present invention provides a compound of formula (I): wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.

公开(公告)号：HRP20220581T1

公开(公告)日：2022-06-10

申请号：HRP20220581

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  DURRANT STEVEN ,  KAY DAVID ,  KNEGTEL RONALD ,  MACCORMICK SOMHAIRLE ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  PINDER JOANNE ,  RUTHERFORD ALISTAIR ,  VIRANI ANISA NIZARALI ,  YOUNG STEPHEN ,  REAPER PHILIP MICHAEL

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

公开(公告)号：AU2018201363B2

公开(公告)日：2020-02-20

申请号：AU2018201363

申请日：2018-02-26

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  DURRANT STEVEN ,  KAY DAVID ,  KNEGTEL RONALD ,  MACCORMICK SOMHAIRLE ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  PINDER JOANNE ,  RUTHERFORD ALISTAIR ,  YOUNG STEPHEN ,  REAPER PHILIP MICHAEL ,  VIRANI ANISA NIZARALI

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: Abstract The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; me thods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermedia tes fo r the prepara tion of the com pound s of this inve ntion; an d method s of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the com parative evaluation of n ew kin ase inhibitors. The compo un ds of this invention have formula (I):whereir the variables are as defined herein

公开(公告)号：CY1120002T1

公开(公告)日：2018-12-12

申请号：CY181100268

申请日：2018-03-02

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  DURRANT STEVEN ,  KAY DAVID ,  KNEGTEL RONALD ,  MACCORMICK SOMHAIRLE ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  PINDER JOANNE ,  RUTHERFORD ALISTAIR ,  VIRANI ANISA NIZARALI ,  YOUNG STEPHEN ,  REAPER PHILIP MICHAEL

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: Ηπαρούσαεφεύρεσηαναφέρεταισεενώσειςπυραζίνηςχρήσιμεςωςαναστολείςκινάσηςπρωτεΐνης ATR. Ηεφεύρεσηαναφέρεται, επίσης, σεφαρμακευτικώςαποδεκτέςσυνθέσειςπουπεριέχουντιςενώσειςαυτήςτηςεφεύρεσης, μεθόδουςθεραπευτικήςαγωγήςδιαφόρωνασθενειών, διαταραχώνκαικαταστάσεων, μεχρήσητωνενώσεωναυτήςτηςεφεύρεσης, διαδικασίεςγιατηνπαρασκευήτωνενώσεωναυτήςτηςεφεύρεσης, ενδιάμεσαγιατηνπαρασκευήτωνενώσεωναυτήςτηςεφεύρεσηςκαιμεθόδουςχρήσηςτωνενώσεωνσε in vitro εφαρμογές, όπωςη μελέτηκινασώνσεβιολογικάκαιπαθολογικάφαινόμενα, ημελέτηοδώνμεταγωγήςενδοκυτταρικώνσημάτωνπουδιαμεσολαβείταιαπότέτοιεςκινάσεςκαιτησυγκριτικήαξιολόγησηνέωναναστολέωνκινάσης. Οιενώσειςαυτήςτηςεφεύρεσηςέχουντύπο (I): όπουοιμεταβλητέςείναιόπωςορίζονταιστοπαρόν.

公开(公告)号：RS56995B1

公开(公告)日：2018-05-31

申请号：RSP20180262

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  DURRANT STEVEN ,  KAY DAVID ,  KNEGTEL RONALD ,  MACCORMICK SOMHAIRLE ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  PINDER JOANNE ,  RUTHERFORD ALISTAIR ,  VIRANI ANISA NIZARALI ,  YOUNG STEPHEN ,  REAPER PHILIP MICHAEL

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

公开(公告)号：PL2376485T3

公开(公告)日：2018-05-30

申请号：PL09798991

申请日：2009-12-18

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  DURRANT STEVEN ,  KAY DAVID ,  KNEGTEL RONALD ,  MACCORMICK SOMHAIRLE ,  MORTIMORE MICHAEL ,  O'DONNELL MICHAEL ,  PINDER JOANNE ,  RUTHERFORD ALISTAIR ,  VIRANI ANISA NIZARALI ,  YOUNG STEPHEN ,  REAPER PHILIP MICHAEL

IPC: A61K31/497 ,  C07D413/04 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

公开(公告)号：AU2013201630B2

公开(公告)日：2016-12-01

申请号：AU2013201630

申请日：2013-03-19

Applicant: VERTEX PHARMA

Inventor： BINCH HAYLEY ,  MORTIMORE MICHAEL ,  DAVIS CHRIS ,  BOYALL DEAN ,  EVERITT SIMON ,  ROBINSON DANIEL ,  RAMAYA SHARN ,  FRAYSSE DAMIEN ,  STUDLEY JOHN ,  MILIER ANDREW ,  O'DONNELL MICHAEL ,  RUTHERFORD ALISTAIR ,  PINDER JOANNE

IPC: C07D239/02 ,  A61K31/505

Abstract: Abstract Disclosed are aminopyrimidine compounds useful as inhibitors of protein kinases. Also disclosed are pharmaceutically acceptable compositions comprising the compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions and disorders. Processes for preparing the compounds are also disclosed.

公开(公告)号：AU2016203378A1

公开(公告)日：2016-06-23

申请号：AU2016203378

申请日：2016-05-24

Applicant: VERTEX PHARMA

Inventor： BINCH HAYLEY ,  MORTIMORE MICHAEL ,  DAVIS CHRIS ,  BOYALL DEAN ,  EVERITT SIMON ,  ROBINSON DANIEL ,  RAMAYA SHARN ,  FRAYSSE DAMIEN ,  STUDLEY JOHN ,  MILIER ANDREW ,  O'DONNELL MICHAEL ,  RUTHERFORD ALISTAIR ,  PINDER JOANNE

IPC: C07D239/02 ,  A61K31/505

Abstract: Compounds and pharmaceutically acceptable compositions thereof that are useful as inhibitors of protein kinases. These compounds are represented by formula I: RY N Q,,RI or a pharmaceutically acceptable salt thereof, wherein R', RX, R , Q, and Ht are as defined herein. These compounds and pharmaceutically acceptable compositions thereof are useful for inhibiting kinases in vitro, in vivo, and ex vivo. Such uses include treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases. Other uses include the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.